Jiangsu Hengrui Medicine Co Ltd Total Liabilities
Jiangsu Hengrui Medicine Co Ltd total liabilities. Based on the latest financial reports, Jiangsu Hengrui Medicine Co Ltd (600276) has total liabilities worth CN¥8.30 Billion CNY (≈ $1.21 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Jiangsu Hengrui Medicine Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Jiangsu Hengrui Medicine Co Ltd (1997–2024)
Total liabilities of Jiangsu Hengrui Medicine Co Ltd from 1997 to 2024. This chart illustrates how Jiangsu Hengrui Medicine Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Jiangsu Hengrui Medicine Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Jiangsu Hengrui Medicine Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Hengrui Medicine Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
United Microelectronics Corporation
TW:2303
|
Taiwan | NT$193.20 Billion |
|
BASF SE
F:BASA
|
Germany | €41.84 Billion |
|
eBay Inc
NASDAQ:EBAY
|
USA | $13.27 Billion |
|
ArcelorMittal SA ADR
NYSE:MT
|
USA | $42.33 Billion |
|
United Microelectronics
NYSE:UMC
|
USA | $193.20 Billion |
|
Danske Bank A/S
CO:DANSKE
|
Denmark | Dkr3.62 Trillion |
|
Franco-Nevada Corporation
TO:FNV
|
Canada | CA$680.39 Million |
Liability Composition Analysis (1997–2024)
This chart breaks down Jiangsu Hengrui Medicine Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 600276 current and non-current assets.
Liquidity & Leverage Metrics
Jiangsu Hengrui Medicine Co Ltd Total Liabilities Ratios Explained
Jiangsu Hengrui Medicine Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Hengrui Medicine Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Hengrui Medicine Co Ltd (1997–2024)
The table below shows the annual total liabilities of Jiangsu Hengrui Medicine Co Ltd from 1997 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥4.05 Billion ≈ $591.97 Million |
+47.03% |
| 2023-12-31 | CN¥2.75 Billion ≈ $402.62 Million |
-30.20% |
| 2022-12-31 | CN¥3.94 Billion ≈ $576.82 Million |
+6.70% |
| 2021-12-31 | CN¥3.69 Billion ≈ $540.61 Million |
-6.29% |
| 2020-12-31 | CN¥3.94 Billion ≈ $576.92 Million |
+50.54% |
| 2019-12-31 | CN¥2.62 Billion ≈ $383.23 Million |
+2.16% |
| 2018-12-31 | CN¥2.56 Billion ≈ $375.12 Million |
+22.29% |
| 2017-12-31 | CN¥2.10 Billion ≈ $306.74 Million |
+44.00% |
| 2016-12-31 | CN¥1.46 Billion ≈ $213.01 Million |
+27.81% |
| 2015-12-31 | CN¥1.14 Billion ≈ $166.66 Million |
+42.91% |
| 2014-12-31 | CN¥796.98 Million ≈ $116.62 Million |
+41.21% |
| 2013-12-31 | CN¥564.40 Million ≈ $82.59 Million |
+25.42% |
| 2012-12-31 | CN¥450.01 Million ≈ $65.85 Million |
+2.40% |
| 2011-12-31 | CN¥439.47 Million ≈ $64.31 Million |
+4.44% |
| 2010-12-31 | CN¥420.80 Million ≈ $61.58 Million |
+26.04% |
| 2009-12-31 | CN¥333.85 Million ≈ $48.85 Million |
+45.21% |
| 2008-12-31 | CN¥229.91 Million ≈ $33.64 Million |
-39.58% |
| 2007-12-31 | CN¥380.51 Million ≈ $55.68 Million |
+89.24% |
| 2006-12-31 | CN¥201.07 Million ≈ $29.42 Million |
+13.53% |
| 2005-12-31 | CN¥177.10 Million ≈ $25.92 Million |
-31.18% |
| 2004-12-31 | CN¥257.33 Million ≈ $37.66 Million |
-52.99% |
| 2003-12-31 | CN¥547.34 Million ≈ $80.09 Million |
+38.71% |
| 2002-12-31 | CN¥394.60 Million ≈ $57.74 Million |
+9.30% |
| 2001-12-31 | CN¥361.03 Million ≈ $52.83 Million |
+15.09% |
| 2000-12-31 | CN¥313.71 Million ≈ $45.91 Million |
+4.16% |
| 1999-12-31 | CN¥301.17 Million ≈ $44.07 Million |
+34.45% |
| 1998-12-31 | CN¥224.00 Million ≈ $32.78 Million |
+15.83% |
| 1997-12-31 | CN¥193.38 Million ≈ $28.30 Million |
-- |
About Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and… Read more